回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌

Huisheng oral liquid combined with single drug nedaplatin chemoradiotherapy in treatment of unresectable locally advanced non-small cell lung cancer

目的探讨回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌的临床疗效。方法 2009年3月～2012年3月采用应用回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌48例,并与同期同步放化疗47例患者进行比较,观察近期疗效、体质量及不良反应。结果治疗组患者的CR、SD、ORR高于对照组,差异有统计学意义(P<0.05);而且治疗组患者的体质量高于对照组,两者比较差异有统计学意义(P<0.05)。治疗组患者血液学毒性明显减轻,出现2级及以上白细胞减少、血小板降低和贫血的病例明显少于对照组。结论回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌,可有效改善患者生活质量、增效减毒等作用,可作为一种有效的辅助治疗晚期非小细胞肺癌的手段。

Objective To explore the clinical effect of Huisheng oral liquid combined with single drug nedaplatin chemoradiotherapy in treatment of unreseetable locally advanced non-small cell lung cancer. Methods 48 cases of unresectable locally advaneed non-small cell lung cancer from March 2009 to March 2012 by the application of huishengkoufuye combined single drug nedaplatin chemoradiotherapy,which was compared with concurrent chemotherapy and 47 patients were compared. Body mass and observing the recent curative effect,adverse reaction were compared in two groups of patients. Results The patients in the treatment group CR,SD,ORR higher than that of the control group,the difference was statistically signifieant（P 〈 0.05）; and the body quality of patients in the treatment group than in the control group,there were significant difference between them（P 〈 0.05）. Patients in the treatment .f group were hematologic toxicity significantly reduced,2 level and ahove,leucopenia,thrombocytopenia and anemia were significantly less than the control group. Conclusion Huisheng oral liquid combined with single drug nedaplatin chemoradiotherapy in treatment of unresectable locally advanced non-small cell lung cancer,which can effectively improve the quality of life of patients with attenuated,synergistic effect.It Can be used as an effective adjuvant therapy in the treatment of advanced non-small cell lung cancer.